Clinical Trial Update: AZD3427 Effects on Renal Perfusion in Heart Failure Patients With Reduced Ejection Fraction and Renal Impairment [Phase 1]

View source ↗

Summary

A Phase 1 trial of AZD3427 evaluating renal perfusion in patients with heart failure with reduced ejection fraction and renal impairment was terminated; the upd…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction
• Renal Impairment

Drugs mentioned

• AZD3427

Snippet

Sponsor: AstraZeneca | Conditions: Heart Failure With Reduced Ejection Fraction (HFrEF), Renal Impairment | Phase 1 | Status: TERMINATED